4D Molecular Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Emeryville, CA
FDMT chart
What traders are saying about $FDMT
Latest posts4D Molecular Therapeutics, Inc. news
- BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $33
Moomoo ·
- 4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
marketbeat.com ·
- HC Wainwright & Co. reiterates Buy rating on 4D Molecular Therapeutics, $36 price target
TradingView ·
- 4D Molecular Therapeutics Rings the Nasdaq Stock Market Closing Bell
Nasdaq ·
- 4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day - Slideshow (NASDAQ:FDMT) 2026-10-21
Seeking Alpha ·
- 4D Molecular Therapeutics Rings the Closing Bell
Nasdaq ·
- Transcript : 4D Molecular Therapeutics, Inc. - Analyst/Investor Day
www.marketscreener.com ·
- Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsight
Yahoo Finance ·
- Scott Bizily, 4D Molecular Therapeutics CLO, sells $20,993 in stock
Investing.com ·
- Form 4 4D Molecular Therapeutics Inc: Scott Bizily (CLO) For: 16 October
Investing.com India ·
- 4DMT Announces New Employment Inducement Grants
Yahoo Finance ·
- 4DMT to Host Investor Day on October 21, 2026
Yahoo Finance ·
4D Molecular Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $85.2M | $37,000 | $20.7M | $3.1M |
| Net income | -$140.1M | -$160.9M | -$100.8M | -$107.5M |
| Diluted EPS | $-2.42 | $-2.98 | $-2.58 | $-3.32 |
| Total assets (year end) | $566.7M | $560.4M | $339.9M | $261.8M |
| Cash and equivalents (year end) | $60.2M | $149.3M | $249.1M | $52.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About 4D Molecular Therapeutics, Inc.
- Ticker
- FDMT (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Emeryville, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1650648
- Former names
- 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
Frequently asked questions
What exchange is 4D Molecular Therapeutics, Inc. listed on?
4D Molecular Therapeutics, Inc. trades on the Nasdaq under the ticker symbol FDMT.
What industry is 4D Molecular Therapeutics, Inc. in?
4D Molecular Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is 4D Molecular Therapeutics, Inc. headquartered?
4D Molecular Therapeutics, Inc.'s business address on file with the SEC is in Emeryville, CA.
When does 4D Molecular Therapeutics, Inc.'s fiscal year end?
4D Molecular Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did 4D Molecular Therapeutics, Inc. report?
4D Molecular Therapeutics, Inc. reported $85.2M in revenue for calendar year 2025, according to its SEC filings.